tetano
Editor, Senior Moderator
BMJ Open
. 2024 Jul 17;14(7):e081627.
doi: 10.1136/bmjopen-2023-081627. Biomarker of severity in hospitalised patients with COVID-19: a retrospective study
Fen-Hong Qian[SUP] 1 [/SUP], Yu-Xue Liu[SUP] 2 [/SUP], Yu Cao[SUP] 2 [/SUP], Jing Huang[SUP] 2 [/SUP], Rong-Hao Zhu[SUP] 2 [/SUP]
Affiliations
Background: The novel COVID-19 was rapidly spreading and was highly contagious. COVID-19 caused over 6 million deaths worldwide, with high mortality rates, particularly in severe cases.
Objective: This study aimed to investigate whether serum albumin-neutrophil count to lymphocyte count ratio (NLR) score (ANS) could be used as a prognostic indicator of COVID-19 severity.
Design: A retrospective study.
Participants: Based on the WHO diagnostic criteria, patients were classified as either non-severe (n=270) or severe (n=100).
Primary and secondary outcome measures: NLR, serum albumin level and ANS.
Main results: The NLR of patients with severe disease was significantly higher than that of those with non-severe disease. Serum albumin levels were significantly lower in patients with severe disease than in those with non-severe disease. The cut-off values representing the maximum potential effectiveness of serum albumin and NLR were 33.5 g/L and 8.25, respectively, according to the Youden index. In patients with severe COVID-19, we observed that the serum albumin level, NLR and ANS were independent prognostic indicators of severe COVID-19 using logistic analysis. The relative risk of severe COVID-19 was 7.65 (95% CI 3.72 to 15.75, p<0.05) in the ANS 2 group compared with that in ANS 0.
Conclusions: ANS could be used as a prognostic indicator of COVID-19 severity.
Keywords: COVID-19; Pulmonary Disease; Retrospective Studies.
. 2024 Jul 17;14(7):e081627.
doi: 10.1136/bmjopen-2023-081627. Biomarker of severity in hospitalised patients with COVID-19: a retrospective study
Fen-Hong Qian[SUP] 1 [/SUP], Yu-Xue Liu[SUP] 2 [/SUP], Yu Cao[SUP] 2 [/SUP], Jing Huang[SUP] 2 [/SUP], Rong-Hao Zhu[SUP] 2 [/SUP]
Affiliations
- PMID: 39019644
- DOI: 10.1136/bmjopen-2023-081627
Background: The novel COVID-19 was rapidly spreading and was highly contagious. COVID-19 caused over 6 million deaths worldwide, with high mortality rates, particularly in severe cases.
Objective: This study aimed to investigate whether serum albumin-neutrophil count to lymphocyte count ratio (NLR) score (ANS) could be used as a prognostic indicator of COVID-19 severity.
Design: A retrospective study.
Participants: Based on the WHO diagnostic criteria, patients were classified as either non-severe (n=270) or severe (n=100).
Primary and secondary outcome measures: NLR, serum albumin level and ANS.
Main results: The NLR of patients with severe disease was significantly higher than that of those with non-severe disease. Serum albumin levels were significantly lower in patients with severe disease than in those with non-severe disease. The cut-off values representing the maximum potential effectiveness of serum albumin and NLR were 33.5 g/L and 8.25, respectively, according to the Youden index. In patients with severe COVID-19, we observed that the serum albumin level, NLR and ANS were independent prognostic indicators of severe COVID-19 using logistic analysis. The relative risk of severe COVID-19 was 7.65 (95% CI 3.72 to 15.75, p<0.05) in the ANS 2 group compared with that in ANS 0.
Conclusions: ANS could be used as a prognostic indicator of COVID-19 severity.
Keywords: COVID-19; Pulmonary Disease; Retrospective Studies.